synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-10. Numbers and descriptions here follow the published literature rather than marketing material.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
== History == On August 10, 1863, the Napa Valley Register first published. It was founded by J.I. Horrell as a pro-Union paper, in contrast to the pro-Succession Napa Echo. By 1864, the newspaper had dropped “Valley” from its name, becoming simply the Napa Register, until returning to the original name over a century later. Editor R.T. Montgomery retired from the paper in January 1866. He returned that May and sold it to N.E. White in January 1868. White left after six months and Montgomery returned again, only to later sell the Register a second time in November 1869 to R.D. Hopkins, formerly editor of the Vallejo Recorder. Hopkins sold to Rev. George W. Henning and George M. Francis in February 1872. The Register moved to daily publication in December 1872. Henning sold out to Charles A. Gardner in May 1873. Gardner left after a few years to run the St. Helena Star. George M. Francis became sole owner of the Register in 1878, upon the death of his business partner. Francis was succeeded in ownership by his son George H. Francis in 1932. The paper remained with Francis and various partners until 1958, when it was sold to Scripps League Newspapers. Scripps was acquired by Pulitzer in 1996, and Pulitzer was acquired by Lee Enterprises in 2005. Dan Evans became the paper's editor in March 2022, and he soon unveiled a newly reconstituted editorial board that October. The board was made up of three members of the newspaper's staff and seven community members. It aimed to assist in driving the official opinion of the paper. In April 2023, the paper laid off two employees.
=== Skeletal muscle === In 1998, skeletal muscle was identified as an endocrine organ due to its now well-established role in the secretion of myokines. The use of the term myokine to describe cytokines and other peptides produced by muscle as signalling molecules was proposed in 2003.
== Endogenous ligands == FPR2, also known as the LXA4 receptor or ALX/FPR2, was initially identified as a high-affinity receptor for the arachidonic acid metabolite lipoxin A4 (LXA4). It was later found to also bind the related metabolites aspirin-triggered lipoxin A4 (ATL, or 15-epi-LXA4), and the docosahexaenoic acid derivative resolvin D1 (RvD1). These three lipid mediators act to inhibit and resolve inflammation. Originally classified as an orphan receptor and termed RFP, FPR2 was discovered by screening myeloid cell-derived libraries using a formyl-methionyl-leucyl-phenylalanine (FMLP)-like probe. In addition to LXA4, ATL, RvD1, and FMLP, FPR2 interacts with a wide range of polypeptides, proteins, and their derivatives. These ligands contribute to processes beyond inflammation, including obesity, neurodegeneration, reproduction, and cancer. Nevertheless, FPR2 is best known for mediating the anti-inflammatory and pro-resolving actions of lipoxins and resolvins. A partial list of FPR2/ALX ligands and their proposed inflammatory effects (based on in vitro and animal studies) includes:
=== Genetic variations === An epigenetic mechanism (hypermethylation of CpG islands in the NET gene promoter region) that results in reduced expression of the noradrenaline (norepinephrine) transporter and consequently a phenotype of impaired neuronal reuptake of norepinephrine has been implicated in both postural orthostatic tachycardia syndrome and panic disorder. rs5569 is a variant of SLC6A2.
Chemical ionization (CI) is a soft ionization technique used in mass spectrometry. This was first introduced by Burnaby Munson and Frank H. Field in 1966. This technique is a branch of gaseous ion-molecule chemistry. Reagent gas molecules (often methane or ammonia) are ionized by electron ionization to form reagent ions, which subsequently react with analyte molecules in the gas phase to create analyte ions for analysis by mass spectrometry. Negative chemical ionization (NCI), charge-exchange chemical ionization, atmospheric-pressure chemical ionization (APCI) and atmospheric pressure photoionization (APPI) are some of the common variants of the technique. CI mass spectrometry finds general application in the identification, structure elucidation and quantitation of organic compounds as well as some utility in biochemical analysis. Samples to be analyzed must be in vapour form, or else (in the case of liquids or solids), must be vapourized before introduction into the source.
Sources: en.wikipedia.org
=== Performance === Early onset of fatigue Decreased aerobic capacity (VO2 max) Poor physical performance Inability to complete workouts Delayed recovery Overtraining can affect the athlete's athletic ability and other areas of life, such as performance in studies or the workforce. An overtrained athlete who is suffering from physical and/or psychological distress could also have trouble socializing with friends and family, studying for an exam, or preparing for work.
2) Order 1993 (S.I. 1993/1821) Occupational Pension Schemes (Preservation of Benefit) Amendment Regulations 1993 (S.I. 1993/1822) Offshore Safety (Repeals and Modifications) Regulations 1993 (S.I. 1993/1823) Export of Goods (Control) (Amendment No. 4) Order 1993 (S.I. 1993/1825) Financial Services (Disclosure of Information) (Designated Authorities) (No. 7) Order 1993 (S.I. 1993/1826) Church of England (Legal Aid) Rules 1993 (S.I. 1993/1840) Diocesan Chancellorship Regulations 1993 (S.I. 1993/1841) Ecclesiastical Judges and Legal Officers (Fees) Order 1993 (S.I. 1993/1842) Legal Officers (Annual Fees) Order 1993 (S.I. 1993/1843) Parochial Fees Order 1993 (S.I. 1993/1844) Local Government Superannuation (Investments) Regulations 1993 (S.I. 1993/1848) Highways (Traffic Calming) Regulations 1993 (S.I. 1993/1849) Education (Mandatory Awards) Regulations 1993 (S.I. 1993/1850) Social Security (Invalid Care Allowance) Amendment (No. 2) Regulations 1993 (S.I. 1993/1851) Assisted Areas Order 1993 (S.I. 1993/1877) Seed Potatoes (Amendment) Regulations 1993 (S.I. 1993/1878) Public Telecommunication System Designation (City of London Telecommunications Ltd) Order 1993 (S.I. 1993/1879) Public Telecommunication System Designation (Ionica L3 Ltd) Order 1993 (S.I. 1993/1880) Companies Act 1989 (Recognised Supervisory Bodies) (Periodical Fees) Regulations 1993 (S.I. 1993/1881) Learning for Work (Scottish Enterprise and Highlands and Islands Enterprise Programmes) Order 1993 (S.I. 1993/1882) Norway Lobsters (Prohibition of Method of Fishing) Order 1993 (S.I.
In 1843, lithium carbonate was used to treat bladder and kidney stones. In 1859, some doctors recommended the compound for a number of ailments, including gout, urinary calculi, rheumatism, mania, depression, and headache. In 1948, John Cade discovered the anti-manic effects of lithium ions. This finding led to lithium carbonate's use as a psychiatric medication to treat mania, the elevated phase of bipolar disorder. Mogens Schou and others continued Cade's research. They found that lithium is effective against both mania and depression, and has preventative effects. Lithium is also unique among medications in that it has anti-suicide properties in people with bipolar disorder or recurrent depression. It has been shown to dramatically reduce the risk of suicide by 87% in clinical trials. In addition to its effects on suicide, lithium also reduces the risk of death from all causes in people with mood disorders. Prescription lithium carbonate from a pharmacy is suitable for use as medicine in humans but industrial lithium carbonate is not since it may contain unsafe levels of toxic heavy metals or other toxicants. After ingestion, lithium carbonate is dissociated into pharmacologically active lithium ions (Li+) and (non-therapeutic) carbonate, with 300 mg of lithium carbonate containing approximately 8 mEq (8 mmol) of lithium ion. The usual dosage of lithium is 600-900 mg/day for the maintenance treatment of bipolar disorder.
Immunogen — an antigen that is capable of inducing an immune response, i.e., it is immunogenic. Antigen is often used interchangeably with this term, but this is not, strictly speaking, correct. All immunogens are antigens, but not all antigens are immunogens. The antigen within a vaccine is often referred to as an immunogen, even if, strictly speaking, its purified form cannot induce immune responses (requiring adjuvants to do so). For simplicity, many sources use the term "antigen" in place of "immunogen," but these terms should not be regarded as interchangeable. Allergen – A substance capable of causing an allergic reaction in sensitized individuals. The reaction may result after exposure via ingestion, inhalation, injection, or contact with skin. Tolerogen – A substance that invokes immune tolerance. This property is related to its molecular properties and circumstances such as route of administration. Superantigen – A class of antigens that cause non-specific activation of T-cells, resulting in polyclonal T-cell activation and massive cytokine release. Immunoglobulin-binding protein – Proteins such as protein A, protein G, and protein L that are capable of binding to antibodies at positions outside of the antigen-binding site (paratope). These are sometimes known as B cell superantigens. Epitope – The specific part of an antigen that is bound by an antibody (or T cell receptor), its antigenic determinant.Antigenic molecules, normally "large" biological polymers, usually present surface features that can act as points of interaction for specific antibodies.
Sources: en.wikipedia.org
=== Alternative classifications === There is an increasing discussion about whether the differences between species adequately represents the variability found within the genus Cannabis. There are five chemotaxonomic types of cannabis: one with high levels of THC, one which is more fibrous and has higher levels of CBD, one that is an intermediate between the two, another one with high levels of cannabigerol (CBG), and the last one almost without cannabinoids. There has also been a recent movement to characterize strains based on their reported subjective effects.
Additionally, it reacts with NADPH-dependent acetoacetyl-coenzyme A reductase, also known as PhaB, in a pathway that produces polyester polyhydroxyalkanoate (PHA). The reduction of acetoacetyl-coA by Pha creates (R)-3-hydroxybutyryl-CoA, which polymerizes to PHA. The pathway is present in bacteria such as Ralstonia eutropha and the PCC6803 strain of Synechocystis. Mover over, Acetoacetyl-CoA is involved with neuronal development involving lipogenesis and providing fats and cholesterol for neuronal cells.
==== 2800–2899 ==== Scottish Electricity Boards (Dissolution) Order 1993 (S.I. 1993/2802) Road Traffic Act 1991 (Commencement No. 8 and Transitional Provisions) Order 1993 (S.I. 1993/2803) Road Traffic (Special Parking Areas) (London Boroughs of Camden, Hackney and Hounslow) Order 1993 (S.I. 1993/2804) Meldon Quarry Branch Line Order 1993 (S.I. 1993/2805) Foreign Compensation (Financial Provisions) (No. 2) Order 1993 (S.I. 1993/2806) Libya (United Nations Sanctions) Order 1993 (S.I. 1993/2807) Libya (United Nations Sanctions) (Dependent Territories) Order 1993 (S.I. 1993/2808) State Immunity (Federal States) Order 1993 (S.I. 1993/2809) Education and Libraries (Northern Ireland) Order 1993 (S.I. 1993/2810) Libya (United Nations Sanctions) (Channel Islands) Order 1993 (S.I. 1993/2811) Libya (United Nations Sanctions) (Isle of Man) Order 1993 (S.I. 1993/2812) Local Government Act 1988 (Defined Activities) (Exemption) (Wales) Order 1993 (S.I. 1993/2813) British Railways (Penalty Fares) Act 1989 (Activating No. 11) Order 1993 (S.I. 1993/2814) Central Manchester National Health Service Trust (Change of Name) Order 1993 (S.I. 1993/2815) Cleveland Ambulance National Health Service Trust (Establishment) Amendment Order 1993 (S.I. 1993/2816) Education (School Information) (Amendment) (England) Regulations 1993 (S.I. 1993/2824) Area Boards (Dissolution) Order 1993 (S.I. 1993/2825) Collecting Societies (Returns) Regulations 1993 (S.I. 1993/2826) Education (No. 2) Act 1986 (Amendment) (No. 2) Order 1993 (S.I. 1993/2827) Education (Recognised Awards) (Richmond College) Order 1993 (S.I.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.